Akebia Therapeutics (AKBA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Si ...

Regions Financial (RF) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a chang ...

Kiora Pharmaceuticals, Inc. (KPRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following yea ...

Investors might want to bet on Corteva, Inc. (CTVA) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a ...

East West Bancorp (EWBC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since ...

Investors might want to bet on Taysha Gene Therapies, Inc. (TSHA) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since ...

Plumas Bancorp (PLBC) came out with quarterly earnings of $1.05 per share, missing the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.50%. A quarter ago, it was expected that this company would post earnings of $1.13 per share when it actually produced earnings of $1.2, delivering a surprise of +6.19%.Over the last four quarters, the company ha ...

Ferrari (RACE) is a Zacks Rank #1 (Strong Buy) that has an D for Value and an A for Growth. A recent earnings beat has this stock in the spotlight. This luxury auto maker will report earnings again at the end of the month and with the economy remaining resilient we might see a boost in sales. If that continues the stock will grow into is rather high valuation.  Let’s learn more about why this stock is the Bull of the Day.Description                                               Ferrari NV is a holding compa ...

The price trend for TIM S.A. Sponsored ADR (TIMB) has been bearish lately and the stock has lost 6.4% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Stree ...

BioMarin Pharmaceutical (BMRN) closed the last trading session at $56.62, gaining 3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $96.69 indicates a 70.8% upside potential.The mean estimate comprises 26 short-term price targets with a standard deviation of $14.53. While the lowest estimate of $65.00 indicates a 14.8% increase from the current price level, the most optimistic ana ...